Coenzyme Q10 serum levels in Huntington's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 68, 2004, Pages 111-116

  Andrich, J ^a   Saft, C ^a   Gerlach, M ^a,b   Schneider, B ^a   Arz, A ^a   Kuhn, W ^a,c   Muller Th ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b Clinical Neurochemistry   (Germany)

^c Leopoldina Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; TETRABENAZINE; UBIDECARENONE; DRUG DERIVATIVE; UBIQUINONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; ENZYME THERAPY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MITOCHONDRION; PRIORITY JOURNAL; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; BLOOD; ENZYMOLOGY; MIDDLE AGED; NONPARAMETRIC TEST;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; UBIQUINONE;

EID: 4544267059     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0579-5_13     Document Type: Article

References (30)

1. Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, Cabello A (1998) Complex I defect in muscle from patients with Huntington's disease. Ann Neurol 43: 397-400
2. Beal MF (1994) Neurochemistry and toxin models in Huntingtons disease. Curr Opin Neurol 7: 542-547
3. Beal MF (1999) Mitochondria, NO and neurodegeneration. Biochem Soc Symp 66: 43-54
4. Cooper JM, Schapira AH (1997) Mitochondrial dysfunction in neurodegeneration. J Bioenerg Biomembr 29: 175-183
5. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q(10) and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22: 1592-1599
6. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A (1996) Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 39: 132-136
7. Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M (2000) Altered redox state of platelet coenzyme Q(10) in Parkinson's disease. J Neural Transm 107: 41-48
8. Gu M, Gash MT, Mann VM, JavoyAgid F, Cooper JM, Schapira AHV (1996) Mitochondrial defect in Huntington's disease on caudate nucleus. Ann Neurol 39: 385-389
9. Huntington Study Group (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 11: 136-142
10. Kasparova S, Sumbalova Z, Kucharska J, Bystricky P, Mlynarik V, Gvozdjakova A (2002) Effect of coenzyme Q(10) on energy metabolism in aged rats with Huntington's disease. J Mol Cell Cardiol 34: A84
11. Keene CD, Rodrigues CMP, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC (2001) A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol 171: 351-360
12. Kieburtz K, Koroshetz W, McDermott M, Beal MF, Greenamyre JT, Ross CA, Shoulson I, Cudkowicz ME, Sexton P, Skeuse C, Rosas D, Jenkins B, Rosenblatt A, Sherr M, Hersch S, Cellar J, Guttman M, Brown C, Como PG, Marshall F, DeMarcaida JA, Zimmerman C, Marder K, Moskowitz C, Polanco C, Beltre J, Shannon K, Jaglin JA, Niederman F, Ashizawa T, Hunter C, Hunter C, Hauser R, Walker A, Gauger L, Hahn MA, Delgado H, Dawson T, Siemers E, Seeberger L, Dingmann C, Dubinsky R, Gray C, Weiner WJ, Rodriguez-Batemen D, Albin RL, Wernette K, Harrison M, Rost-Ruffner E, Paulsen J, Rodnitzky RL, Dobson J, Vining L, Suchowersky O, Pantella C, Saint-Hilaire MH, Furtado J, Martin W, Wieler M, Walker F, Hunt V, Raymond L, Almqvist E, Rubin A, Blair B, Marek K, Caplan K, Baker D, Bracht A, Casaceli C, Orme C, Rudolph A, Rumfola L, Schifitto G, Shinaman A, Sulimowicz K, Watts A, Eapen S, Zhang L (2001) A randomized, placebo-controlled trial of coenzyme Q(10) and remacemide in Huntington's disease. Neurology 57: 397-404
13. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Energy metabolism defects in Huntington's disease and effects of coenzyme Q(10). Ann Neurol 41: 160-165
14. Matthews RT, Yang L, Browne S, Baik M, Beal MF (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 95: 8892-8897
15. Maurer I, Moller HJ (1997) Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 174: 255-259
16. Müller T, Büttner T, Gholipour AF, Kuhn W (2003) Coenzyme Q(10) supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 341: 201-204
17. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S (1999) Coenzyme Q10 in health and disease. Eur J Clin Nutr 53: 764-770
18. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I (2001) Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57: 658-662
19. Penney Jr JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41: 689-692
20. Przedborski S, Jackson-Lewis V, Muthane U, Jiang H, Ferreira M, Naini AB, Fahn S (1993) Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34: 715-723
21. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8: 397-407
22. Shults CW, Haas RH, Passov D, Beal MF (1997) Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42: 261-264
23. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos BL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q(10) in early Parkinson disease - Evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550
24. Smith PR, Cooper JM, Govan GG, Harding AE, Schapira AH (1993) Smoking and mitochondrial function: a model for environmental toxins. Q J Med 86: 657-660
25. Tabrizi SJ, Schapira AHV (1999b) Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem Soc Symp 66: 99-110
26. Tabrizi SJ, Cooper JM, Xuereb JH, Schapira AHV (1997) Mechanisms involved in the pathogenesis of Huntington's disease. Ann Neurol 42: T202
27. Tabrizi SJ, Cleeter MWJ, Xuereb J, Taanman JW, Cooper JM, Schapira AHV (1999a) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45: 25-32
28. Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AHV (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47: 80-86
29. Tabrizi SJ, Rajagopalan B, Styles P, Manners D, Schapira AH, Warner TT (2002) Creatine therapy for Huntington's disease (HD): clinical and-(31)phosphorous magnetic resonance spectroscopy (P-31 MRS) findings in a one year pilot. Mov Disord 17: S319
30. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AHV, Warner TT (2003) Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 61: 141-142